// App-Quantinova.ai

BSH2020‐EP‐073 : Real‐world treatment patterns, adverse events and clinical outcomes in patients with chronic lymphocytic leukaemia treated with ibrutinib in the United Kingdom

Researchers

Presenter

  • J. Xie

Principal Investigators

  • A. S. M. Yong

  • C. Waweru

  • T.-A. Sorof

  • R. K. Goyal

  • K. L. Davis

  • P. Hillmen

Medical Centers

  • AstraZeneca, Gaithersburg, MD

  • AstraZeneca, Luton

  • Acerta Pharma

  • RTI Health Solutions, NC, USA

  • StJamess University Hospital, Leeds, UK

Locations

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

  • Hypertension

Biomarkers

  • Bruton tyrosine kinase

  • Tumor protein p53

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • Bendamustine

  • chlorambucil

  • fludarabine tablet

  • Venetoclax

  • Ibrutinib

  • Rituximab

  • L-Tyrosine

  • TP53

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved